Showing results (151-160 of 168) with videos related to

Sort By:
Pageof 17
Diabetologia|June 1, 1991
Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effectsS Martin, G Schernthaner, J Nerup, et al.
The American Journal of Physiology|May 1, 1993
Insulin resistance is localized to skeletal but not heart muscle in type 1 diabetesP Nuutila, J Knuuti, U Ruotsalainen, et al.
Acta Endocrinologica|May 1, 1981
Increase in thyroxine-binding globulin (TBG) in lysinuric protein intoleranceB A Lamberg, J Perheentupa, J Rajantie, et al.
The Journal of Clinical Investigation|June 1, 1992
Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivoP Nuutila, V A Koivisto, J Knuuti, et al.
The Journal of Physiology|December 22, 1999
Sodium nitroprusside increases human skeletal muscle blood flow, but does not change flow distribution or glucose uptakeO P Pitkanen, H Laine, J Kemppainen, et al.
European Journal of Haematology|February 23, 2007
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomasP Schütt, J Passon, P Ebeling, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 8, 2000
Effect of calcitriol on bone loss after cardiac or lung transplantationP Sambrook, N K Henderson, A Keogh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2003
Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patientsM R Nowrousian, S Waschke, P Bojko, et al.
Diabetes, Obesity & Metabolism|February 21, 2008
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylureaA J Garber, J E Foley, M A Banerji, et al.
Bone Marrow Transplantation|June 20, 2017
An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trialA Grigg, B Butcher, B Khodr, et al.
Pageof 17